bioMérieux – Third-Quarter 2019 Business Review

22 October, 2019

Marcy l'Étoile (France), October 22, 2019 – bioMérieux, a world leader in the field of in vitro diagnostics, released its business review for the nine months ended September 30, 2019.

  • Organic growth of 6.8% at constant exchange rates and scope of consolidation over the first nine months of the year:
    • €1,928 million in sales
    • Up 10.3% as reported
  • Acceleration of organic growth in sales to reach 9.6% in the third quarter driven by strong momentum across all Regions
  • 2019 targets:
    • Organic growth in sales of around 7%
    • Contributive operating income before non-recurring items of between €385 million and €400 million.

Alexandre Mérieux, Chairman and Chief Executive Officer, said: “bioMérieux performed well in the third quarter of 2019. Fast-paced growth continued, driven primarily by a solid increase in reagent sales that reached 8% growth for the first nine months of the year. Given our business outlook and a high basis of comparison in the fourth quarter, organic growth in sales should come in at around 7.0% for the full year and our target margin is confirmed.”


Consolidated sales came in at €1,928 million for the nine months ended September 30, 2019, versus €1,748 million for the same period one year earlier. As expected, growth in sales (at constant exchange rates and scope of consolidation) maintained the momentum seen in the second quarter, reaching 9.6% in the third quarter. Organic growth and reported growth for the first nine months of the year reached 6.8% and 10.3% respectively, powered by a positive currency effect of €42 million that was primarily due to a stronger US dollar and the €20 million impact of changes in the Group’s scope that was mostly linked with the consolidation of Hybiome and Invisible Sentinel sales.

About bioMérieux

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics for over 50 years, bioMérieux is present in more than 43 countries and serves more than 160 countries with the support of a large network of distributors. In 2018, revenues reached €2.4 billion, with over 90% of international sales.

bioMérieux provides diagnostic solutions (systems, reagents, software, and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the Euronext Paris stock market
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP


Corporate website: Investor website:


Investor Relations

Sylvain Morgeau
Tel.: +33 (0)4 78 87 22 37

Media Relations

Aurore Sergeant
Tel.: +33 (0)4 78 87 20 53

Image Sept
Laurence Heilbronn
Tel.: +33 (0)1 53 70 74 64

Claire Doligez
Tel.: +33 (0)1 53 70 74 48

Download the Full Press Release:

Pioneering Diagnostics